Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.

[1]  J. Lee,et al.  Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial , 2018, International Journal of Radiation Oncology*Biology*Physics.

[2]  D. de Ruysscher,et al.  Progression‐Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  Xiaoxia Zhu,et al.  Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. , 2018, Journal of thoracic disease.

[6]  C. Vallejos,et al.  The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. , 2018, Lung cancer.

[7]  S. Yom,et al.  Is there a benefit to locally consolidative therapy for oligometastatic non-small cell lung cancer? , 2017, Annals of translational medicine.

[8]  S. Barni,et al.  Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time? , 2017, European journal of cancer.

[9]  M. Qiu,et al.  Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. , 2017, Journal of thoracic disease.

[10]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[11]  A. Cardona,et al.  Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials , 2016, Oncology.

[12]  Ping Yang,et al.  Prognostic effect of liver metastasis in lung cancer patients with distant metastasis , 2016, Oncotarget.

[13]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[14]  H. Jang,et al.  Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review , 2016, Oncotarget.

[15]  Martin A Lodge,et al.  Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. , 2016, Radiology.

[16]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Hassan Lemjabbar-Alaoui,et al.  Lung cancer: Biology and treatment options. , 2015, Biochimica et biophysica acta.

[18]  Ahmedin Jemal,et al.  Global trends of lung cancer mortality and smoking prevalence. , 2015, Translational lung cancer research.

[19]  Matthew Meyerson,et al.  Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  E. Marchiori,et al.  PET/CT imaging in lung cancer: indications and findings , 2015, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[21]  R. Boellaard,et al.  Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC. , 2014, Lung cancer.

[22]  G. Rodrigues,et al.  Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. , 2013, Lung cancer.

[23]  M. Ginsberg,et al.  Epidemiology of Lung Cancer , 2013, Seminars in Interventional Radiology.

[24]  R. Perez-Padilla,et al.  [National consensus of diagnosis and treatment of non-small cell lung cancer]. , 2013, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[25]  C. Villarreal-Garza,et al.  Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation , 2011, Radiation oncology.

[26]  S. Digumarthy,et al.  Staging of non-small cell lung cancer using integrated PET/CT. , 2009, AJR. American journal of roentgenology.

[27]  Y. Nishiyama,et al.  Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[29]  J. Crowley,et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[32]  A. Jemal,et al.  Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.